CLRB

+ Watchlist + Portfolio

Cellectar Biosciences, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.62
52-Week Range: $2.20 – $6.52
Market Cap: $24.48M
P/E (TTM): —
EPS (TTM): -2.21
Dividend Yield: —

Advanced Metrics

Price/Book: 0.72
PEG Ratio: —
Return on Equity: -119.57%
Return on Assets: -58.44%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 6.66
Debt/Equity: 0.05
Total Debt: $1.53M
Free Cash Flow: $-12.27M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-7.70M

CLRB Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$18.27M	$27.27M	$26.14M	$11.50M
Selling, General & Admin	$10.55M	$11.69M	$25.64M	$11.48M
Operating Expenses	$28.81M	$38.96M	$51.78M	$22.98M
Operating Income	-$28.81M	-$38.96M	-$51.78M	-$22.98M
EBITDA	-$28.67M	-$38.77M	-$51.49M	-$22.77M
Pretax Income	-$31.85M	-$42.83M	-$44.52M	-$21.79M
Income Tax	-$60.00K	-$60.00K	$66.00K	$0.00
Net Income	-$31.79M	-$42.77M	-$44.58M	-$21.79M
Diluted EPS	-121.50	-105.00	-41.89	-8.35
Diluted Shares	235188	407385	1.24M	2.61M

CLRB Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$19.87M	$9.56M	$23.29M	$13.20M
Current Assets	$20.53M	$10.45M	$24.25M	$14.04M
Total Assets	$21.59M	$12.08M	$25.47M	$14.98M
Current Liabilities	$11.50M	$25.36M	$9.39M	$4.75M
Total Debt	$603.83K	$552.98K	$494.00K	$409.59K
Total Liabilities	$13.44M	$27.23M	$11.18M	$6.44M
Retained Earnings	-$159.99M	-$202.76M	-$247.34M	-$269.13M
Shareholders' Equity	$8.15M	-$15.16M	$14.29M	$8.54M
Working Capital	$9.03M	-$14.91M	$14.86M	$9.29M

CLRB Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$25.22M	-$32.38M	-$47.58M	-$23.12M
Capital Expenditure	-$225.97K	-$864.04K	-$104.19K	-$5.88K
Free Cash Flow	-$25.45M	-$33.24M	-$47.69M	-$23.12M
Depreciation & Amortisation	$148.44K	$192.38K	$291.65K	$213.60K
Stock-Based Compensation	$1.45M	$2.41M	$4.27M	$2.26M
Investing Cash Flow	-$225.97K	-$864.04K	-$104.19K	-$5.88K
Financing Cash Flow	$9.61M	$22.94M	$61.41M	$13.03M
Net Change in Cash	-$15.84M	-$10.30M	$13.72M	-$10.09M

CLRB Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$3.43M	$2.39M	$2.52M	$3.16M	$3.01M
Selling, General & Admin	$2.97M	$3.65M	$2.33M	$2.53M	$2.79M
Operating Expenses	$6.40M	$6.04M	$4.85M	$5.69M	$5.79M
Operating Income	-$6.40M	-$6.04M	-$4.85M	-$5.69M	-$5.79M
EBITDA	-$6.34M	-$5.98M	-$4.80M	-$5.64M	-$5.79M
Pretax Income	-$6.60M	-$5.45M	-$4.44M	-$5.30M	-$5.65M
Net Income	-$6.60M	-$5.45M	-$4.44M	-$5.30M	-$5.65M
Diluted EPS	-4.30	-3.39	-1.41	—	-1.33
Diluted Shares	1.54M	1.61M	3.16M	—	4.24M

CLRB Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$13.91M	$11.04M	$12.55M	$13.20M	$8.35M
Current Assets	$14.89M	$12.62M	$13.62M	$14.04M	$9.27M
Total Assets	$16.04M	$13.70M	$14.63M	$14.98M	$11.12M
Current Liabilities	$6.02M	$5.87M	$4.91M	$4.75M	$4.87M
Total Debt	$474.35K	$453.51K	$431.93K	$409.59K	$1.53M
Total Liabilities	$7.79M	$7.61M	$6.63M	$6.44M	$7.78M
Retained Earnings	-$253.95M	-$259.39M	-$263.84M	-$269.13M	-$274.79M
Shareholders' Equity	$8.25M	$6.09M	$8.00M	$8.54M	$3.34M
Working Capital	$8.87M	$6.75M	$8.71M	$9.29M	$4.39M

CLRB Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$9.38M	-$5.12M	-$4.28M	-$4.34M	-$4.85M
Capital Expenditure	—	—	—	—	-$3.38K
Free Cash Flow	-$9.38M	-$5.12M	-$4.28M	-$4.35M	-$4.85M
Depreciation & Amortisation	$56.30K	$55.56K	$52.28K	$49.46K	-$110.02K
Stock-Based Compensation	$562.74K	$565.39K	$567.79K	$567.79K	$451.87K
Investing Cash Flow	$0.00	$0.00	$0.00	-$5.88K	-$3.38K
Financing Cash Flow	$0.00	$2.25M	$5.79M	$4.99M	—
Net Change in Cash	-$9.38M	-$2.86M	$1.51M	$641.74K	-$4.85M

Market Snapshot

About

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company developing targeted radiotherapies for cancer treatment. Headquartered in Florham Park, New Jersey, the company's proprietary phospholipid ether (PLE) platform selectively delivers radiation to cancer cells and the tumor microenvironment. Cellectar's lead product candidate, iopofosine I 131, is being evaluated for relapsed/refractory multiple myeloma and other hematologic malignancies. The PLE platform's tumor-targeting mechanism offers potential advantages over conventional radiotherapy by concentrating therapeutic radiation while sparing healthy tissue.